300485 赛升药业
已收盘 08-14 15:00:00
资讯
新帖
简况
股市必读：赛升药业新发布《关于公司向金融机构申请综合授信并为子公司提供担保的公告》
证券之星 · 01:46
股市必读：赛升药业新发布《关于公司向金融机构申请综合授信并为子公司提供担保的公告》
赛升药业（300485）披露向金融机构申请综合授信并为子公司提供担保的公告，8月14日股价下跌1.28%
证券之星 · 08-14 22:19
赛升药业（300485）披露向金融机构申请综合授信并为子公司提供担保的公告，8月14日股价下跌1.28%
赛升药业(300485)7月31日股东户数3.09万户，较上期减少1.47%
证券之星 · 08-11
赛升药业(300485)7月31日股东户数3.09万户，较上期减少1.47%
赛升药业：截至2026年7月31日，公司股东户数为30937
证券之星 · 08-11
赛升药业：截至2026年7月31日，公司股东户数为30937
股市必读：赛升药业（300485）7月31日董秘有最新回复
证券之星 · 08-03
股市必读：赛升药业（300485）7月31日董秘有最新回复
赛升药业：截至2026年7月20日，公司股东户数为31400
证券之星 · 07-31
赛升药业：截至2026年7月20日，公司股东户数为31400
太阳药业获巴西ANVISA批准，将生产销售司美格鲁肽
投资观察 · 07-30
太阳药业获巴西ANVISA批准，将生产销售司美格鲁肽
赛升药业(300485.SZ)：达格列净片境内生产药品注册上市许可申请获受理
智通财经 · 07-27
赛升药业(300485.SZ)：达格列净片境内生产药品注册上市许可申请获受理
股市必读：赛升药业（300485）7月23日董秘有最新回复
证券之星 · 07-24
股市必读：赛升药业（300485）7月23日董秘有最新回复
赛升药业(300485)6月30日股东户数3.14万户，较上期增加5.17%
证券之星 · 07-13
赛升药业(300485)6月30日股东户数3.14万户，较上期增加5.17%
赛升药业(300485.SZ)收到注射用甲磺酸萘莫司他药品注册受理通知书
智通财经 · 06-24
赛升药业(300485.SZ)收到注射用甲磺酸萘莫司他药品注册受理通知书
股市必读：赛升药业（300485）6月23日董秘有最新回复
证券之星 · 06-24
股市必读：赛升药业（300485）6月23日董秘有最新回复
赛升药业：以上均为不实传闻
证券之星 · 06-23
赛升药业：以上均为不实传闻
股市必读：赛升药业（300485）6月18日董秘有最新回复
证券之星 · 06-22
股市必读：赛升药业（300485）6月18日董秘有最新回复
赛升药业：公司在研项目K11启动Ⅲ期临床，已完成全部入组
证券之星 · 06-18
赛升药业：公司在研项目K11启动Ⅲ期临床，已完成全部入组
赛升药业：截至2026年5月29日，公司股东户数为29850
证券之星 · 06-08
赛升药业：截至2026年5月29日，公司股东户数为29850
赛升药业：目前公司生产经营正常
证券之星 · 06-03
赛升药业：目前公司生产经营正常
赛升药业(300485)5月20日股东户数2.95万户，较上期减少2.81%
证券之星 · 05-25
赛升药业(300485)5月20日股东户数2.95万户，较上期减少2.81%
赛升药业（300485）披露2025年年度权益分派实施公告，5月20日股价下跌3.88%
证券之星 · 05-20
赛升药业（300485）披露2025年年度权益分派实施公告，5月20日股价下跌3.88%
股市必读：赛升药业(300485)股东户数3.03万户，较上期减少1.64%
证券之星 · 05-18
股市必读：赛升药业(300485)股东户数3.03万户，较上期减少1.64%
加载更多
公司概况
公司名称：
北京赛升药业股份有限公司
所属行业：
医药制造业
上市日期：
2015-06-26
主营业务：
北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药、其他药品、其他业务。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。
发行价格：
38.46
{"stockData":{"symbol":"300485","market":"SZ","secType":"STK","nameCN":"赛升药业","latestPrice":10,"timestamp":1786691004000,"preClose":10.13,"halted":0,"volume":10419500,"delay":0,"changeRate":-0.0128,"floatShares":274000000,"shares":482000000,"eps":-0.0431,"marketStatus":"已收盘","change":-0.13,"latestTime":"08-14 15:00:00","open":10.1,"high":10.25,"low":9.85,"amount":104000000,"amplitude":0.0395,"askPrice":10.01,"askSize":70,"bidPrice":10,"bidSize":278,"shortable":0,"etf":0,"ttmEps":-0.0431,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":5,"adr":0,"adjPreClose":10.13,"symbolType":"stock","openAndCloseTimeList":[[1786671000000,1786678200000],[1786683600000,1786690800000]],"highLimit":11.14,"lowLimit":9.12,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":481666400,"isCdr":false,"pbRate":1.45,"roa":"--","roe":"0.14%","epsLYR":0.03,"committee":0.512531,"marketValue":4817000000,"turnoverRate":0.0381,"status":1,"floatMarketCap":2738000000},"requestUrl":"/m/hq/s/300485","defaultTab":"news","newsList":[{"id":"2660170575","title":"股市必读：赛升药业新发布《关于公司向金融机构申请综合授信并为子公司提供担保的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660170575","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660170575?lang=zh_cn&edition=full","pubTime":"2026-08-17 01:46","pubTimestamp":1786902372,"startTime":"0","endTime":"0","summary":"公司公告汇总关于公司向金融机构申请综合授信并为子公司提供担保的公告北京赛升药业股份有限公司于2026年8月14日发布公告，公司向杭州银行股份有限公司北京分行申请人民币6,500万元综合授信额度，其中使用3,030.63万元用于开立融资性保函，为子公司沈阳君元药业有限公司向中国光大银行卢森堡分行申请外债贷款提供担保。本次担保后，公司累计对外担保金额为人民币3,030.63万元，占最近一期经审计净资产的0.90%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0028","300485","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147164","title":"赛升药业（300485）披露向金融机构申请综合授信并为子公司提供担保的公告，8月14日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147164","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659147164?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:19","pubTimestamp":1786717149,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，赛升药业报收于10.0元，较前一交易日下跌1.28%，最新总市值为48.17亿元。赛升药业于近日发布公告称，公司向杭州银行股份有限公司北京分行申请人民币6,500万元综合授信额度，其中使用3,030.63万元用于开立融资性保函，为子公司沈阳君元药业有限公司向中国光大银行卢森堡分行申请外债贷款提供担保。本次担保后，公司累计对外担保金额为人民币3,030.63万元，占最近一期经审计净资产的0.90%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400040204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","BK0239","300485","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658964129","title":"赛升药业(300485)7月31日股东户数3.09万户，较上期减少1.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658964129","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658964129?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:32","pubTimestamp":1786440768,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2026年7月31日公司股东户数为3.09万户，较7月20日减少463.0户，减幅为1.47%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至7月31日，生物制品行业平均股东户数为3.53万户。根据统计，赛升药业2026年7月20日至2026年7月31日，主力资金净流出3717.69万元，游资资金净流出1404.46万元，散户资金净流入5122.15万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100028183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300485","BK0046","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658963212","title":"赛升药业：截至2026年7月31日，公司股东户数为30937","url":"https://stock-news.laohu8.com/highlight/detail?id=2658963212","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658963212?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:15","pubTimestamp":1786410915,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)08月10日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到7月31日公司股东人数是多少？谢谢赛升药业回复：您好，截至2026年7月31日，公司股东户数为30937。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100007297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0028","300485","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656343899","title":"股市必读：赛升药业（300485）7月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2656343899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656343899?lang=zh_cn&edition=full","pubTime":"2026-08-03 02:15","pubTimestamp":1785694514,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，赛升药业报收于8.8元，上涨3.29%，换手率2.43%，成交量6.65万手，成交额5810.63万元。董秘最新回复投资者： 请问截止到7月20日公司股东人数是多少？谢谢董秘： 您好，截至2026年7月20日，公司股东户数为31400。交易信息汇总资金流向7月31日主力资金净流出409.02万元，占总成交额7.04%；游资资金净流出329.58万元，占总成交额5.67%；散户资金净流入738.59万元，占总成交额12.71%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0028","300485","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655356120","title":"赛升药业：截至2026年7月20日，公司股东户数为31400","url":"https://stock-news.laohu8.com/highlight/detail?id=2655356120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655356120?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:30","pubTimestamp":1785486626,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到7月20日公司股东人数是多少？谢谢赛升药业回复：您好，截至2026年7月20日，公司股东户数为31400。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100027181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0012","300485","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176697432","title":"太阳药业获巴西ANVISA批准，将生产销售司美格鲁肽","url":"https://stock-news.laohu8.com/highlight/detail?id=1176697432","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176697432?lang=zh_cn&edition=full","pubTime":"2026-07-30 00:45","pubTimestamp":1785343529,"startTime":"0","endTime":"0","summary":"7月29日，太阳药业宣布，已获得巴西卫生监管机构ANVISA的批准，可在该国生产并销售司美格鲁肽。这一关键进展，为公司在拉丁美洲市场的扩张铺平了道路。太阳药业计划携手当地合作伙伴Hypera Pharma，共同将司美格鲁肽引入巴西市场。司美格鲁肽作为一种GLP-1受体激动剂，在糖尿病和肥胖症治疗领域备受关注。太阳药业此番布局，无疑将提升其在南美市场的竞争力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0028","300485","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654090700","title":"赛升药业(300485.SZ)：达格列净片境内生产药品注册上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2654090700","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654090700?lang=zh_cn&edition=full","pubTime":"2026-07-27 15:52","pubTimestamp":1785138731,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业 发布公告，公司子公司北京赛而生物药业有限公司近日收到了国家药品监督管理局下发的达格列净片境内生产药品注册上市许可申请的《受理通知书》。达格列净是一种SGLT-2抑制剂，由百时美施贵宝发现，后授权给阿斯利康开发及商业化。2012年获欧洲EMA批准，2014年获美国FDA批准。2017年进入中国市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","300485","BK0046","BK0239","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653072228","title":"股市必读：赛升药业（300485）7月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653072228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653072228?lang=zh_cn&edition=full","pubTime":"2026-07-24 01:14","pubTimestamp":1784826854,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，赛升药业报收于8.94元，下跌0.67%，换手率3.73%，成交量10.21万手，成交额9022.1万元。当日关注点交易信息汇总：7月23日主力资金净流出793.49万元，散户资金净流入890.16万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400000998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0046","BK0239","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651026190","title":"赛升药业(300485)6月30日股东户数3.14万户，较上期增加5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651026190","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651026190?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:52","pubTimestamp":1783936354,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2026年6月30日公司股东户数为3.14万户，较5月29日增加1544.0户，增幅为5.17%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.56万户。从股价来看，2026年5月29日至2026年6月30日，赛升药业区间涨幅为6.85%，在此期间股东户数增加1544.0户，增幅为5.17%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300026936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300485","BK0012","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645893830","title":"赛升药业(300485.SZ)收到注射用甲磺酸萘莫司他药品注册受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645893830","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645893830?lang=zh_cn&edition=full","pubTime":"2026-06-24 15:49","pubTimestamp":1782287368,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)发布公告，公司于近日收到国家药品监督管理局下发的注射用甲磺酸萘莫司他药品注册受理通知书。据悉，注射用甲磺酸萘莫司他用于改善胰腺炎的急性症状;治疗弥散性血管内凝血综合征(DIC);用于防止有出血性病变或出血倾向的患者血液体外循环时灌流血液的凝固(血液透析和血浆置换)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0239","BK0028","300485","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645585340","title":"股市必读：赛升药业（300485）6月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645585340","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645585340?lang=zh_cn&edition=full","pubTime":"2026-06-24 01:42","pubTimestamp":1782236530,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，赛升药业报收于9.7元，上涨18.44%，换手率10.95%，成交量29.99万手，成交额2.78亿元。董秘最新回复投资者： 尊敬的董秘您好，补充追问实控人相关传闻事宜：目前市场流传两条相关传闻：1、实控人马骉正在接受证监局立案调查；2、调查涉及实控人体外变相占用上市公司资金。当日关注点交易信息汇总：6月23日主力资金净流入2520.48万元，游资资金净流入1073.5万元，散户资金净流出3593.98万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400001216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300485","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645816258","title":"赛升药业：以上均为不实传闻","url":"https://stock-news.laohu8.com/highlight/detail?id=2645816258","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645816258?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:36","pubTimestamp":1782203767,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)06月23日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，补充追问实控人相关传闻事宜：目前市场流传两条相关传闻：1、实控人马骉正在接受证监局立案调查；2、调查涉及实控人体外变相占用上市公司资金。此前公司仅说明上市公司资金管理合规，并未澄清上述两条传闻的真伪。请问以上市场传闻是否属实？若监管调查已有阶段性结论，烦请同步披露，维护中小投资者知情权，谢谢。赛升药业回复：您好，以上均为不实传闻。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300027984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","300485","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645217016","title":"股市必读：赛升药业（300485）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645217016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645217016?lang=zh_cn&edition=full","pubTime":"2026-06-22 05:07","pubTimestamp":1782076033,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，赛升药业报收于8.15元，上涨0.0%，换手率1.63%，成交量4.45万手，成交额3648.35万元。董秘最新回复投资者： 咨询两个问题：一、实控人相关资金规范整改目前进展如何？药品研发及注册申报存在不确定性，敬请投资者注意投资风险。当日关注点交易信息汇总：6月18日主力资金净流出131.74万元，游资资金净流出169.4万元，散户资金净流入301.14万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200001728.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0012","300485","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644703660","title":"赛升药业：公司在研项目K11启动Ⅲ期临床，已完成全部入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2644703660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644703660?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:51","pubTimestamp":1781769086,"startTime":"0","endTime":"0","summary":"公司在研项目及项目情况可关注公司披露的定期报告及临时公告的相关内容。药品研发及注册申报存在不确定性，敬请投资者注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800023798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0012","BK0028","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641710156","title":"赛升药业：截至2026年5月29日，公司股东户数为29850","url":"https://stock-news.laohu8.com/highlight/detail?id=2641710156","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641710156?lang=zh_cn&edition=full","pubTime":"2026-06-08 15:04","pubTimestamp":1780902253,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)06月08日在投资者关系平台上答复投资者关心的问题。投资者提问：截止6.1日股东户数有多少？赛升药业回复：您好，截至2026年5月29日，公司股东户数为29850。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800013568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","300485","BK0239","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640904044","title":"赛升药业：目前公司生产经营正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2640904044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640904044?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:52","pubTimestamp":1780491130,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司在经营上是否遇到重大困难？自5.6以来贵司以及累计跌幅23%远超创业板指以及板块指数，贵司实控人是否会增持回购提振投资者信心？赛升药业回复：您好，目前公司生产经营正常。未来如有股份回购相关计划，公司将遵照监管要求及时履行信息披露义务，请以公司公告为准。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300044413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0046","300485","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638953132","title":"赛升药业(300485)5月20日股东户数2.95万户，较上期减少2.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638953132","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638953132?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:33","pubTimestamp":1779701630,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2026年5月20日公司股东户数为2.95万户，较5月8日减少852.0户，减幅为2.81%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至5月20日，生物制品行业平均股东户数为3.53万户。从股价来看，2026年5月8日至2026年5月20日，赛升药业区间跌幅为9.98%，在此期间股东户数减少852.0户，减幅为2.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500024646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300485","BK0046","BK0028","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636845319","title":"赛升药业（300485）披露2025年年度权益分派实施公告，5月20日股价下跌3.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636845319","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636845319?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:15","pubTimestamp":1779272119,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，赛升药业报收于9.65元，较前一交易日下跌3.88%，最新总市值为46.48亿元。该股当日开盘10.03元，最高10.03元，最低9.6元，成交额达7674.25万元，换手率为2.88%。公司于近日披露《2025年年度权益分派实施公告》。公告显示，北京赛升药业股份有限公司2025年年度权益分派方案已获2026年4月23日召开的年度股东会审议通过。股权登记日为2026年5月26日，除权除息日为2026年5月27日。现金红利由中国结算深圳分公司代派，部分股东由公司自行派发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000035172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0012","300485","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636153016","title":"股市必读：赛升药业(300485)股东户数3.03万户，较上期减少1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636153016","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636153016?lang=zh_cn&edition=full","pubTime":"2026-05-18 04:08","pubTimestamp":1779048493,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，赛升药业报收于10.16元，下跌1.74%，换手率1.83%，成交量5.02万手，成交额5137.69万元。来自股本股东变化：截至2026年5月8日，公司股东户数环比下降1.64%，户均持股上升至1.59万股，呈现筹码集中趋势。股本股东变化股东户数变动近日赛升药业披露，截至2026年5月8日公司股东户数为3.03万户，较4月30日减少505.0户，减幅为1.64%。户均持股数量由上期的1.56万股增加至1.59万股，户均持股市值为17.02万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800001716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","300485","BK0028","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786908517374,"stockEarnings":[{"period":"1week","weight":0.0384},{"period":"1month","weight":-0.0099},{"period":"3month","weight":-0.0123},{"period":"6month","weight":-0.1088},{"period":"1year","weight":-0.2898},{"period":"ytd","weight":-0.0515}],"compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0072},{"period":"3month","weight":-0.0503},{"period":"6month","weight":-0.0379},{"period":"1year","weight":0.0711},{"period":"ytd","weight":-0.0105}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京赛升药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30937人(较上一季度减少1.47%)","perCapita":"8850股","listingDate":"2015-06-26","address":"北京市大兴区北京经济技术开发区兴盛街8号","registeredCapital":"48166万元","survey":" 北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药、其他药品、其他业务。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。","listedPrice":38.46},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛升药业,300485,赛升药业股票,赛升药业股票老虎,赛升药业股票老虎国际,赛升药业行情,赛升药业股票行情,赛升药业股价,赛升药业股市,赛升药业股票价格,赛升药业股票交易,赛升药业股票购买,赛升药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}